ReviewNPJ breast cancer2026
Preclinical models of breast cancer metastasis: strengths, limitations, and clinical relevance.
Review in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Closing the recapitulation gap in obesity-conditioned TNBC drug development.npj drug discovery · 2026Review
- Cytokine Regulation of the Bone Pre- and Metastatic Niches: Implications for Breast Cancer Dormancy.Cells · 2026Review
- Bridging In Vitro and Murine Breast Cancer Models: Advanced Imaging Across Multiscale Experimental Platforms.Cancers · 2026Review
- We need less animal research, better animal research, and animal research done for the right reasons.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer metastasis remains a leading cause of mortality. Animal models have been instrumental in dissecting the complex metastatic cascade and have provided insights into tumor progression and mechanisms of dissemination to distant organs. However, significant gaps remain, particularly in the context of a highly heterogeneous disease like breast cancer. This review summarizes animal models utilized to study breast cancer metastasis, including mutagen-induced and genetically engineered mouse models, cell line-based syngeneic and xenograft models, patient-derived xenografts, as well as rat and zebrafish models. We summarize the strengths and limitations of each model in recapitulating key stages of metastasis, including the onset of metastasis, organ-specific tropism, and tumor-microenvironment interactions. Additionally, we highlight the importance of these models in preclinical drug testing and personalized therapy. By providing a comprehensive overview, this review aims to guide researchers in choosing the most suitable preclinical breast cancer animal model to effectively address metastasis-related questions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.